Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharma bets on branded drugs in the US
While the company hopes to push into branded speciality drugs, which offer a better value proposition in the US, its core generics business will continue to remain a priority
Alembic slides as Q4 PAT tanks 60% YoY to Rs 10 cr
Alembic declined 2.63% to Rs 87.59 after the company's consolidated net profit tanked 59.53% to Rs 9.61 crore in Q4 FY26, compared to Rs 23.75 crore posted in Q4 FY25.
Alembic Pharmaceuticals consolidated net profit rises 29.20% in the March 2026 quarter
Sales rise 4.41% to Rs 1847.72 crore
Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend
The company also recommended a dividend of ₹12 per equity share of face value ₹2 each for shareholders. Shares of Alembic Pharmaceuticals Ltd ended at ₹782.10, down by ₹4.35, or 0.55%, on the BSE.
Alembic Pharma gains after Q4 PAT climbs 29% YoY to Rs 203 cr
Alembic Pharmaceuticals rose 1.11% to Rs 795.20 after the company's consolidated net profit jumped 29.19% to Rs 202.70 crore in Q4 FY26, compared to Rs 156.89 crore posted in Q4 FY25.
Q4 Results LIVE Updates: JSW Steel, Muthoot react to results; Tata Steel, Power Grid report today
Q4 Results LIVE Updates: Two Nifty 50 companies Tata Steel and Power Grid along with broader market names like ITC Hotels, Hindustan Copper, Godfrey Phillips, Gland Pharma, Cochin Shipyard, Deepak Nitrite, Balrampur Chini, Arvind, Bajaj Electricals, Aarti Drugs, Aether Industries, Alembic Pharma, NCC, NHPC, Premier Energies, SAIL, SJVN, Solara Active Pharma, Symphony, Thangamayil, Triveni Engineering, VST Tillers, are among the companies reporting their earnings today. JSW Steel, Muthoot Finance, Apollo Tyres, Endurance Tech, Voltas, are some of the other result reactions today. Watch this space for all the LIVE updates.
Alembic Pharma gets USFDA tentative nod for generic prostate cancer drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic version of Darolutamide tablets, targeting prostate cancer treatment. The approval is for the 300 mg strength. The drug is a generic version of Nubeqa Tablets. The robust market potential for these tablets suggests promising future growth for Alembic.
Alembic Pharmaceuticals receives USFDA approval for Darolutamide Tablets, 300 mg
Alembic Pharmaceuticals (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Darolutamide Tablets, 300 mg.
Alembic Pharma shares rise on USFDA nod for prostate cancer drug with $3 billion estimated market size
Alembic Pharmaceuticals shares gained after USFDA granted a tentative ANDA nod for Darolutamide Tablets 300 mg, a prostate cancer drug, marking its 238th ANDA approval.
Alembic Pharma gains after receiving USFDA nod for Darolutamide tablets
Alembic Pharmaceuticals rose 1.57% to Rs 780.50 after the company announced that it had received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Darolutamide Tablets, 300 mg.
Technical Stock Calls: Check Kush Bohra's Top Buy Calls Of The Day | May 12, 2026
Top picks include bullish setups in Alembic Pharma and Genus Power, alongside a tactical short position in Blue Star May Futures following its recent earnings announcement.
Alembic Pharmaceuticals receives USFDA approval for Methotrexate Injection
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Methotrexate Injection USP, 50 mg/2 mL (25 mg/mL) Multi-Dose Vials & 1g/40 mL (25 mg/mL) Single Dose Vials.